Innovative Health Initiative (IHI)
IHI will be the home of both ongoing IMI and future IHI projects, seeking to foster the research & innovation ecosystem in Europe
IMI becomes IHI
Conscious that future breakthroughs in healthcare and medical science will be the result of cross-sectorial discoveries, IMI needed to evolve. Europe is at a crossroads, facing increasing challenges on several fronts while at the same time, technological and scientific advances offer new opportunities to solve these challenges. Bridging the gap to address today's health and translational challenges will require a multi-sector public-private partnership.
The successes of IMI and the knowledge gleaned from 14 years of experience and almost 200 projects means that IHI will ensure Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research.
- Pioneer the patient-centred integration of knowledge, technology and products
- Tackle each and every aspect of care to improve lives of patients across Europe and beyond
- Strengthen Europe’s position at the forefront of medical innovation
- Address current and future health challenges
EFPIA members committed nearly 3 billion Euros across IMI1, IMI2 and IHI to progress biomedical research and address patients and societal needs.
How can this Partnership help solve significant current and future health challenges in different healthcare areas?
Read more on the Innovative Health Initiative
* Download here the Industry associations Consortium Agreement template for IHI projects *
Download the multiparty confidentiality agreement template proposed by industry associations for preparing applications for IHI actions.
Featured article
Data Sharing Playbook can unlock health partnerships
Health research collaborations mean sharing data – we can deliver faster if we identify and remove obstacles early, write IHI's Niklas Blomberg and EFPIA's Magda Chlebus.
Read more-
INNODIA: A Success Story in Type 1 Diabetes Research and Treatment (Guest blog)
Type 1 Diabetes (T1D) is an autoimmune disease where the body’s own immune system mistakenly attacks insulin-producing beta cells in the pancreas. It’s an irreversible process, meaning that people living with T1D must rely on lifelong insulin therapy to survive.14.11.24Read Article -
Data Sharing Playbook can unlock health partnerships
Health research collaborations mean sharing data – we can deliver faster if we identify and remove obstacles early, write IHI's Niklas Blomberg and EFPIA's Magda Chlebus.24.07.24Read Article -
Innovative Health Initiative: improving health, improving healthcare
From managing obesity to supporting healthier pregnancy, IHI is advancing people’s health and making health systems more efficient26.03.24Read Article -
IHI Calls 4 and 5: Publication of draft topics and opening of registration to call days
IHI Call Days: Calls 4 & 512.06.23Read Article -
IHI launches new funding round
The Innovative Health Initiative (IHI) has launched its third call for proposals, featuring topics covering rare diseases and mental health, and addressing challenges such as disease prevention, hospital care, and patient-generated evidence.13.12.22Read Article -
Landmark moment for Innovative Health Initiative (IHI)
IHI’s first calls for proposals present an unprecedented opportunity to tackle key EU priorities and unmet medical need in a new way28.06.22Read Article -
The Innovative Health Initiative (IHI) will carry IMI torch
Today we celebrate the launch of the Innovative Health Initiative, the future “home” of both ongoing IMI and future IHI projects.26.01.22Read Article -
Industry partners welcome adoption of Innovative Health Initiative
The Innovative Health Initiative is a unique cross-sectoral initiative aiming at strengthening Europe’s position at the forefront of health innovation.19.11.21Read Article -
A strategic research & innovation agenda for a healthier Europe
A joint statement from COCIR, EFPIA, MedTech Europe, EuropaBio and Vaccines Europe21.06.21Read Article
If you have any questions, please contact the Science Policy team at science-policy@efpia.eu